Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Impact of Copy Number Alterations' Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy.
Libura M, Karabin K, Tyrna P, Czyż A, Makuch-Łasica H, Jaźwiec B, Paluszewska M, Piątkowska-Jakubas B, Zawada M, Gniot M, Trubicka J, Szymańska M, Borg K, Więsik M, Czekalska S, Florek I, Król M, Paszkowska-Kowalewska M, Gil L, Kapelko-Słowik K, Patkowska E, Tomaszewska A, Mądry K, Machowicz R, Czerw T, Piekarska A, Dutka M, Kopińska A, Helbig G, Gromek T, Lewandowski K, Zacharczuk M, Pastwińska A, Wróbel T, Haus O, Basak G, Hołowiecki J, Juszczyński P, Lech-Marańda E, Giebel S, Jędrzejczak WW. Libura M, et al. Among authors: paluszewska m. Cancers (Basel). 2023 Nov 15;15(22):5431. doi: 10.3390/cancers15225431. Cancers (Basel). 2023. PMID: 38001691 Free PMC article.
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Libura M, Bialopiotrowicz E, Giebel S, Wierzbowska A, Roboz GJ, Piatkowska-Jakubas B, Pawelczyk M, Gorniak P, Borg K, Wojtas M, Florek I, Matiakowska K, Jazwiec B, Solarska I, Noyszewska-Kania M, Piechna K, Zawada M, Czekalska S, Salamanczuk Z, Karabin K, Wasilewska K, Paluszewska M, Urbanowska E, Gajkowska-Kulik J, Semenczuk G, Rybka J, Wrobel T, Ejduk A, Kata D, Grosicki S, Robak T, Pluta A, Kominek A, Piwocka K, Pyziak K, Sroka-Porada A, Wrobel A, Przybylowicz A, Wojtaszewska M, Lewandowski K, Gil L, Piekarska A, Knopinska W, Bolkun L, Warzocha K, Kuliczkowski K, Sacha T, Basak G, Jedrzejczak WW, Holowiecki J, Juszczynski P, Haus O. Libura M, et al. Among authors: paluszewska m. Sci Rep. 2021 May 11;11(1):10017. doi: 10.1038/s41598-021-88120-y. Sci Rep. 2021. PMID: 33976256 Free PMC article.
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M, Czyż A, Montesinos P, Armatys A, Helbig G, Hołowiecka A, Pluta A, Zarzycka E, Piątkowska-Jakubas B, Majcherek M, Lewandowski K, Gołos A, Paluszewska M, Podhorecka M, Oleksiuk J, Skręt A, Hawrylecka D, Guzicka-Kazimierczak RE, Wątek M, Gromek T, Charliński G, Grosicki S, Holojda J, Miśkiewicz W, Martinez-Cuadrón D, Sanz MA, Wróbel T, Wierzbowska A, Giebel S. Sobas M, et al. Among authors: paluszewska m. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):105-113. doi: 10.1016/j.clml.2019.09.616. Epub 2019 Sep 30. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31874794
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fernández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanz MA, Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups. Sobas M, et al. Among authors: paluszewska m. Eur J Haematol. 2020 Mar;104(3):162-169. doi: 10.1111/ejh.13346. Epub 2020 Jan 22. Eur J Haematol. 2020. PMID: 31724208
Pericarditis in Patients With Chronic Graft-vs-Host Disease.
Karakulska-Prystupiuk E, Basak G, Dwilewicz-Trojaczek J, Paluszewska M, Boguradzki P, Jędrzejczak W. Karakulska-Prystupiuk E, et al. Among authors: paluszewska m. Transplant Proc. 2018 Sep;50(7):2218-2222. doi: 10.1016/j.transproceed.2018.02.130. Epub 2018 Mar 14. Transplant Proc. 2018. PMID: 30177139
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E, Drozd-Sokołowska J, Waszczuk-Gajda A, Stefaniak A, Dwilewicz-Trojaczek J, Kulikowska A, Chmarzyńska-Mróz E, Basak G, Paluszewska M, Boguradzki P, Jędrzejczak W. Karakulska-Prystupiuk E, et al. Among authors: paluszewska m. Transplant Proc. 2018 Sep;50(7):2212-2217. doi: 10.1016/j.transproceed.2018.02.148. Epub 2018 Mar 14. Transplant Proc. 2018. PMID: 30177138
Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations.
Snarski E, Milczarczyk A, Hałaburda K, Torosian T, Paluszewska M, Urbanowska E, Król M, Boguradzki P, Jedynasty K, Franek E, Wiktor-Jedrzejczak W. Snarski E, et al. Among authors: paluszewska m. Bone Marrow Transplant. 2016 Mar;51(3):398-402. doi: 10.1038/bmt.2015.294. Epub 2015 Dec 7. Bone Marrow Transplant. 2016. PMID: 26642342 Clinical Trial.
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Libura M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, Florek I, Matiakowska K, Jazwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, Jakobczyk M, Karabin K, Paluszewska M, Calbecka M, Gajkowska-Kulik J, Gadomska G, Kielbinski M, Ejduk A, Kata D, Grosicki S, Wierzbowska A, Kyrcz-Krzemien S, Warzocha K, Kuliczkowski K, Skotnicki A, Holowiecki J, Jedrzejczak WW, Haus O. Libura M, et al. Among authors: paluszewska m. Blood. 2016 Jan 21;127(3):360-2. doi: 10.1182/blood-2015-08-662130. Epub 2015 Nov 13. Blood. 2016. PMID: 26567156 Free article. No abstract available.
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. Sanz MA, et al. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15. Ann Hematol. 2015. PMID: 25975975 Clinical Trial.
41 results